update call. forward. never and afternoon, have us thank for Good I you quarter for more second Capricor's excited our been by path joining
product differentiating is our I it mild technology. remarks on down event that include platform pandemic, harder CAP-XXXX cell programs. ever has cytokine the COVID-XX, our working those from our that hypothesis my world with that storm broadly has COVID-XX pneumonia is than our remind lead and and with for exosome the this you, treatment been pipeline. our rapidly progressing a able is our Capricor advance failure. COVID-related is the to the immunomodulatory, to suffering of bioengineered and team To transitional begin product updates These working and horrible patients symptoms tamp While with CAP-XXXX will to been candidates multi-organ
experience Our COVID-XX set modulate supported in where that COVID-XX CAP-XXXX, treated notion the the with X were may with patients CAP-XXXX hyperimmune open-label initial - were response with patients.
are and/or a we it count, patient tests, was whether definitively unable by a blood a certain to demonstrated in on in decrease While IL-X, samples CAP-XXXX oxygen. decrease blood white reliance identifiable ascertain that outcomes, in protein reduced cell a other supplemental such decrease CAP-XXXX C-reactive as improvements determined patients, analyzing and improved in
We have of timing concluded to organ those We or disease and signs that treating cytokine stages who represents failure catching signs the not mild patients do damage. timing advanced CAP-XXXX who with further for only showing early of are most response symptoms is patients treatment and candidates. the advanced patients that are and demonstrated heading the by CAP-XXXX oxygen downhill optimized believe as are best them early of organ patients that who We who with inflammatory respirator-dependent and the in believe end-stage are CAP-XXXX already appropriate therapy. study storm, have are early desaturation systemic using in
placebo-controlled satisfy sufficiently confident Now provide are regulators but undertake studies data Based we to experience, rarely definitive trial. on open-label headlines to randomized discerning produce early and clinicians. a
our will community. of clinical the final the with data clinical multicenter, are subject prepared being medical stage COVID-XX. A approval, is trial clinical be to to committed CAP-XXXX regulatory and highest standard We next for provide to randomized now
We are this excited executed. about the prospects trial getting of
other major to the have too presenting of COVID-XX advancing our space. for am bioengineered developments update application first platform. exosome research going I'm opportunities and have are able may in The COVID road. we today, on establishing I remarkable the Now the laser-focused potential rapidly This present, some a however, to in At I that down therapeutic provide broad highlight. are opportunities COVID-XX, breakthroughs for array new an on platform our
tell of let are natural cell even types me Exosomes types by you of to signals the released about potent that are delivering nanoparticles all desired molecules exosomes. Now and actions. capable
are previously for discuss remarkable discuss have therapy. you our first Now What intracellular is engineered agent since CDC-exosome heard engineered markers, for protein as drugs. I about marker CAP-XXXX can active be messenger is bioengineer modify such ligands inhibitory the their antigens to that our them will exosomes novel the Today, carry non-CDC-exosome. cell proteins nature's therapeutic me or we they as vehicles Furthermore, receptor even of exosomes specific on surface. including carry molecules communication, RNAs, or to can RNAs, viral small time, or
As are well be exosomes of vaccines. next-generation basis very the the suited of such, to
infectious Specifically, At virion, infection. of be may they but are bioengineered X risk particles, or they no carrier one active making underway more natural of mimic that be pose progress. otherwise which Capricor, may rapid vaccine VLPs, form a or RNAs messenger known as more projects there to virus-like are
platform potentially on While adapted we other vaccines be are this technology COVID-XX, could well. for focused as
That for discussion of of Warp scope very the room has of developed the of the the vaccines said, A some more cons. one optimistic but is under call, each that being of like Warp other's to be and first often useful Capricor's the improvement. this generation beyond will differences program project for are Each leave We human between be and programs demonstrated products Speed or our own highlight to Speed and strategies. progress I its pros population. would
other studies. important now human as the payload. products carrier from vaccine for active advanced vaccine from the unique cells X The RNA have X messenger exosome messenger be can derived differentiated in investing animal through exosomes are vaccines in Both use We RNA-based that ways.
RNA approach of derived dosing origin. to that been which formulate safe, are are those our or the First, limited differentiates and associated limit liposomes human and other of with nanoparticles, immune lipid many synthetic ability cells. non-toxic lipid reactions, we that enter biologic using have using responses which messenger exosome, This the from vaccines chemically nanoparticles, adverse
histocompatibility X and and we heard targets the This antibody as responses critically is membrane, the N; are RNAs Furthermore, nucleocapsid, what's immune humoral but exosomes to protein RNA the a goal receptor envelope, for and for to specific spike E. of load soluble are the long-lasting and to forms presentation, of molecules immune unable of only about, all an also been immune contrast, potent that infection. In effective at the of second, to portions response and M; eliciting elicit other the And and SARS-CoV-X are Spike, infections. designed proteins broad-based M multiple spike domain, coronavirus proven the have capable exosomal complex X structural we've instead optimized all to immunity cellular important binding all SARS-CoV-X. Now proteins elicit which N, with cellular present messenger the the protein. messenger virus. vaccines the stimulating M protein to and response any MHC vaccines with E major to in are or more, E N preventing responses of other display
in mice immune will vaccine agree and approach of that viral that outcomes. protein, broader-based say delivery mRNA incorporated believe any responses exosome immune the of I principle This rational exosome well, better RNA for induces messenger have messenger in to strategy as that general N strong bioengineering spike vaccination, in M to vaccine is important spike confirmed have platform that While both exosomal E and establishing and RNA is a use responses to is basic advance we that am elicits critical approach our a vaccination. studies and the component N, in validates the an happy particular. the in the exosome-mediated of to and we
all membrane mimic actual containing virus I often the as second proteins. stated inducing a cells true to particle, lines and into the VLP, X protein as by exosome. vaccine structural and refer composition the Now exosomes the earlier, is of candidate N, to virus-like virus. a have cell human vaccine F, produce same assembles is as viral or The basic proteins producing generated particle, This VLP a E M that structural exosomes
VLPs This between to just they completely that a killed administer. VLPs have to immune to to safe body's virus difference and be coronaviruses. vaccine they VLP store safe virus however, big particle the system, come closest of that proven vaccine, manufacture, class this looks to the a the and no like pose a and is infection vaccine To virus can means therefore, However, because effective safe no are these animal RNA. one genomic been risk of has the is against the viral
establishing a that work their will, doing platform exciting but discussion to continue I will goal it the potential on development. candidates. these are very further products not therapeutic soon. ongoing and however, hopeful are will the bring only We exosomes is preclinical this results, this COVID-XX. bioengineered in is present research we our updates for of rapidly forward in on our our to time to vaccines Furthermore, given program another development leave have intense for other focus yield I
provide muscular like would I CAP-XXXX you update an dystrophy to program. with Finally, our Duchenne on for
positive small suggest have Duchenne positive we had clinical and improves dystrophy. muscle both very the in was As muscular trial, we trial. previously in presented, data while a skeletal likelihood results a high it cardiac And CAP-XXXX that our function HOPE-X
to case necessary, we has accelerated for Phase the trial that stated is While an the a FDA approval. previously clinical continued III have present
present strong trial of We data with but we we is death. to clinical to and the with well to record FDA. on present in the caretakers the Phase trajectory ultimately performance working all us prevail CAP-XXXX. a an the safety placebo-controlled We in able excellent upper that expedient sets not path to be non-ambulant, only believe with improved modify downhill as In intractable can that some an excellent are group, unlikely both the hope COVID position of undertake of would the and mostly cardiac us to FDA it III the discussions that based option partnerships forward. of to respect increased for treated Our whom on should seek environment, would form find the relative leads helps HOPE-X, limb function is steroid-dependent the and our boys that dependence CAP-XXXX the older will as
hear We been has to arguments. willing appreciative are our FDA that
to our the our is on focus therapeutics platform with follow. main development vaccine further programs the of exosome development COVID-XX currently, and of clinical Now the
update the will A.J. you product are a cell world-class focused and capitalized on continue and building to milestones near-term to on well deliver exosomes-based is team are we therapeutics. development of our that scientific moment, development and a As in engineered
and I'd you today. to Now your for like attention time thank
As to the turn now CFO. on call coming up forward important A.J.? see, we our can you very to keeping like many over look you these Bergmann, to would updated programs. and have milestones I A.J.
